EA201100544A1 - Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли - Google Patents

Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли

Info

Publication number
EA201100544A1
EA201100544A1 EA201100544A EA201100544A EA201100544A1 EA 201100544 A1 EA201100544 A1 EA 201100544A1 EA 201100544 A EA201100544 A EA 201100544A EA 201100544 A EA201100544 A EA 201100544A EA 201100544 A1 EA201100544 A1 EA 201100544A1
Authority
EA
Eurasian Patent Office
Prior art keywords
opioid
manufacture
combination
pain
prevention
Prior art date
Application number
EA201100544A
Other languages
English (en)
Inventor
Дженнифер Риггс-Сотье
Original Assignee
Нектар Терапьютикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нектар Терапьютикс filed Critical Нектар Терапьютикс
Publication of EA201100544A1 publication Critical patent/EA201100544A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

В данном изобретении описано применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения или предотвращения боли.
EA201100544A 2006-11-07 2007-11-07 Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли EA201100544A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85761006P 2006-11-07 2006-11-07

Publications (1)

Publication Number Publication Date
EA201100544A1 true EA201100544A1 (ru) 2012-01-30

Family

ID=39365136

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201100544A EA201100544A1 (ru) 2006-11-07 2007-11-07 Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
EA200970459A EA200970459A1 (ru) 2006-11-07 2007-11-07 Лекарственные формы и совместное введение опиоидного агониста и опиоидного антагониста

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200970459A EA200970459A1 (ru) 2006-11-07 2007-11-07 Лекарственные формы и совместное введение опиоидного агониста и опиоидного антагониста

Country Status (12)

Country Link
US (1) US20100284960A1 (ru)
EP (1) EP2097083A2 (ru)
JP (1) JP2010509227A (ru)
KR (1) KR20090087442A (ru)
CN (1) CN101534827A (ru)
AU (1) AU2007317788B2 (ru)
BR (1) BRPI0718554A2 (ru)
CA (1) CA2667259A1 (ru)
EA (2) EA201100544A1 (ru)
IL (1) IL198249A0 (ru)
MX (1) MX2009004965A (ru)
WO (1) WO2008057579A2 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4814488B2 (ja) * 2001-10-18 2011-11-16 ネクター セラピューティックス 重合体共役物オピオイドアンタゴニスト
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP3222293B1 (en) * 2007-03-12 2019-11-27 Nektar Therapeutics Oligomer-opioid agonist conjugates
US7691878B2 (en) 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2009029252A1 (en) 2007-08-27 2009-03-05 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ATE502939T1 (de) 2007-08-27 2011-04-15 Theravance Inc Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
EP2231589B1 (en) 2007-12-11 2013-02-13 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists
AU2008335210B2 (en) 2007-12-11 2013-10-10 Theravance Biopharma R&D Ip, Llc 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
ES2431354T3 (es) 2008-04-01 2013-11-26 Theravance, Inc. Derivados de 2-aminotetralina como antagonistas del receptor de opioide mu
MX2010011727A (es) * 2008-05-07 2010-11-30 Nektar Therapeutics Administracion oral de antagonistas opioides que actuan perifericamente.
MX347741B (es) * 2008-09-16 2017-05-10 Nektar Therapeutics Opioides pegilados con bajo potencial de abuso.
TWI449685B (zh) 2008-12-10 2014-08-21 Theravance Inc ３－羧基丙基－胺基四氫化萘化合物之結晶型
WO2012040651A2 (en) * 2010-09-24 2012-03-29 QRxPharma Ltd. Controlled release formulations of opioids
CU24317B1 (es) 2010-09-30 2018-02-08 Astrazeneca Ab Conjugado de naloxol-peg cristalino
AU2012336030B2 (en) * 2011-11-07 2017-09-14 Nektar Therapeutics Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
JP6279547B2 (ja) 2012-04-17 2018-02-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
WO2017041095A1 (en) 2015-09-03 2017-03-09 Allegheny-Singer Research Institute Hydrophilic fentanyl derivatives
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
DE102015121366A1 (de) * 2015-12-08 2017-06-08 Dendropharm Gmbh Analgetische Zusammensetzungen mit Nanocarriern und ihre Verwendung
EP3228307A1 (en) 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法
CN109364078A (zh) * 2018-12-13 2019-02-22 上海市嘉定区中心医院 纳洛酮在制备镇痛药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JP4814488B2 (ja) * 2001-10-18 2011-11-16 ネクター セラピューティックス 重合体共役物オピオイドアンタゴニスト
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN102895666B (zh) * 2003-12-16 2015-08-19 尼克塔治疗公司 化学改性的小分子
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone

Also Published As

Publication number Publication date
EP2097083A2 (en) 2009-09-09
CN101534827A (zh) 2009-09-16
AU2007317788A1 (en) 2008-05-15
US20100284960A1 (en) 2010-11-11
BRPI0718554A2 (pt) 2013-11-19
IL198249A0 (en) 2009-12-24
AU2007317788B2 (en) 2013-05-02
KR20090087442A (ko) 2009-08-17
WO2008057579A3 (en) 2008-12-04
CA2667259A1 (en) 2008-05-15
EA200970459A1 (ru) 2009-12-30
MX2009004965A (es) 2009-06-05
JP2010509227A (ja) 2010-03-25
WO2008057579A2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
CY1122724T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
IL207439B (en) Use of an antagonistic antibody against calcitonin gene-related peptide (cgrp) for the preparation of a drug for the prevention and/or treatment of joint pain
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
ME02414B (me) Tretman kronove bolesti lakvinimodom
HK1129594A1 (en) Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
CY1108201T1 (el) Συσκευες διαδερματικης απελευθερωσης οπιοειδους που ειναι ανθεκτικες στην παραβιαση
TR201907874T4 (tr) Düşük sülfat fukanlar kullanarak fibröz yapışmaları ya da inflamatuar hastalıkları inhibe etmeye yönelik farmasötik kompozisyonlar ve yöntemler.
UA112434C2 (uk) Антигензв'язувальний білок, який специфічно зв'язується з всма
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
IL207440A (en) Use of an antagonist antibody against a related peptide-calcitonin gene (cgrp) in the preparation of a drug for the prevention and / or treatment of chronic pain and / or symptoms of chronic pain and pharmaceutical preparations and kits containing it
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
ECSP088619A (es) Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
MY153669A (en) Ocular allergy treatments field of the invention
WO2011026125A3 (en) Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
EA200970529A1 (ru) Антивирусная композиция и способ ее применения
WO2007135505A3 (en) Veterinary pharmaceutical compositions for the treatment of pain and inflammation
WO2007087457A3 (en) Combination therapy for the treatment of neovascular disorders
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.